Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Professional Summary
Professional Education
- Fellowship: Stanford University Hematology and Oncology Fellowship (2015) CA
- Residency: Stanford University Internal Medicine Residency (2012) CA
- Internship: Stanford University Internal Medicine Residency (2011) CA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2017)
- Board Certification, Oncology, American Board of Internal Medicine (2017)
- Board Certification: American Board of Internal Medicine, Internal Medicine (2013)
- PhD, University of Michigan, Immunology (2010)
- Medical Education: University of Michigan Health System (2010) MI
Honors & Awards
- Dean's Postdoctoral Fellowship, Stanford University (2014)
- Distinction in Academics and Research, University of Michigan, Ann Arbor (2010)
- Fellow Award, Leukemia and Lymphoma Society (2014-)
- Membership, Alpha Omega Alpha (2009)
- Predoctoral Fellowship Award, National Science Foundation (2002)
- Wiliam Dodd Robinson Award, University of Michigan, Ann Arbor (2010)
- Young Investigator Award, Journal of Clinical Oncology, Conquer Cancer Foundation (2015)
Publications
-
Tumor antigen discovery through translation of the cancer genome.
Khodadoust, M. S., & Alizadeh, A. A. (2014). Tumor antigen discovery through translation of the cancer genome. Immunologic Research, 58(2-3), 292–99. -
Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Xu, G., Quon, A., … Hoppe, R. T. (2015). Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. International Journal of Radiation Oncology, Biology, Physics, 92(1), 99–106. -
Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.
Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., Schalkwyk, A. S., … Gotlib, J. (2016). Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia, 30(4), 947–50. -
The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity
Kappes, F., Waldmann, T., Mathew, V., Yu, J., Zhang, L., Khodadoust, M. S., … Markovitz, D. M. (2011). The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. GENES & DEVELOPMENT, 25(7), 673–678. -
DEK expression in melanocytic lesions
Kappes, F., Khodadoust, M. S., Yu, L., Kim, D. S. L., Fullen, D. R., Markovitz, D. M., & Ma, L. (2011). DEK expression in melanocytic lesions. HUMAN PATHOLOGY, 42(7), 932–938. -
Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene
Khodadoust, M. S., Verhaegen, M., Kappes, F., Riveiro-Falkenbach, E., Cigudosa, J. C., Kim, D. S. L., … Soengas, M. S. (2009). Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene. CANCER RESEARCH, 69(16), 6405–6413. -
DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress
Kappes, F., Fahrer, J., Khodadoust, M. S., Tabbert, A., Strasser, C., Mor-Vaknin, N., … Ferrando-May, E. (2008). DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. MOLECULAR AND CELLULAR BIOLOGY, 28(10), 3245–3257. -
The DEK nuclear autoantigen is a secreted chemotactic factor
Mor-Vaknin, N., Punturieri, A., Sitwala, K., Faulkner, N., Legendre, M., Khodadoust, M. S., … Markovitz, D. M. (2006). The DEK nuclear autoantigen is a secreted chemotactic factor. MOLECULAR AND CELLULAR BIOLOGY, 26(24), 9484–9496. -
p300/CBP-associated factor drives DEK into interchromatin granule clusters
Cleary, J., Sitwala, K. V., Khodadoust, M. S., Kwok, R. P. S., Mor-Vaknin, N., Cebrat, M., … Markovitz, D. M. (2005). p300/CBP-associated factor drives DEK into interchromatin granule clusters. JOURNAL OF BIOLOGICAL CHEMISTRY, 280(36), 31760–31767. -
Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
Khodadoust, M. S., Olsson, N., Wagar, L. E., Haabeth, O. A. W., Chen, B., Swaminathan, K., … Alizadeh, A. A. (2017). Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. NATURE, 543(7647), 723-? -
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery. -
Profiling Tumor Infiltrating Immune Cells with CIBERSORT.
Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M., & Alizadeh, A. A. (2018). Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods in Molecular Biology (Clifton, N.J.), 1711, 243–59. -
T-cell immunopeptidomes reveal cell subtype surface markers derived from intracellular proteins.
Olsson, N., Schultz, L. M., Zhang, L., Khodadoust, M. S., Narayan, R., Czerwinski, D. K., … Elias, J. E. (2018). T-cell immunopeptidomes reveal cell subtype surface markers derived from intracellular proteins. Proteomics. -
Transcript-indexed ATAC-seq for precision immune profiling.
Satpathy, A. T., Saligrama, N., Buenrostro, J. D., Wei, Y., Wu, B., Rubin, A. J., … Chang, H. Y. (2018). Transcript-indexed ATAC-seq for precision immune profiling. Nature Medicine. -
Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.
Dai, J., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S., Weng, W.-K. K., & Kim, Y. H. (2018). Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome. JAMA Dermatology. -
Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst.
Erdrich, J., Schaberg, K., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., … Beausang, J. F. (2018). Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. Cold Spring Harbor Molecular Case Studies. -
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018785246. -
Pembrolizumab in mycosis fungoides and Sezary syndrome: Updated results of the CITN multicenter Phase 2 study
Khodadoust, M. S., Rook, A. H., Porcu, P., Foss, F., Moskowitz, A., Shustov, A. R., … Kim, Y. H. (2018). Pembrolizumab in mycosis fungoides and Sezary syndrome: Updated results of the CITN multicenter Phase 2 study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study
Bagot, M., Porcu, P., William, B., Vermeer, M., Whittaker, S., Wolff, C. R., … Kim, Y. (2018). IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study. EUROPEAN JOURNAL OF CANCER, 101, S29. -
Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome.
Torrey, H., Khodadoust, M., Tran, L., Baum, D., Defusco, A., Kim, Y. H., & Faustman, D. L. (2018). Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome. Leukemia. -
B cell lymphomas present immunoglobulin neoantigens.
Khodadoust, M. S., Olsson, N., Chen, B., Sworder, B., Shree, T., Liu, C. L., … Alizadeh, A. A. (2018). B cell lymphomas present immunoglobulin neoantigens. Blood. -
Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies
Torrey, H., Defusco, A., Baum, D., Rhabar, Z., Khodadoust, M., Kim, Y. H., & Faustman, D. L. (2018). Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies. CANCER IMMUNOLOGY RESEARCH, 6(9). -
Reply to J. Wang et al.
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2019). Reply to J. Wang et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801907. -
Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Final Results from a Phase 2 Multicenter Study
Khodadoust, M. S., Rook, A., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., … Kim, Y. H. (2018). Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Final Results from a Phase 2 Multicenter Study. BLOOD. AMER SOC HEMATOLOGY. -
The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Horwitz, S. M., Feldman, T. A., Hess, B. T., Khodadoust, M. S., Kim, Y. H., Munoz, J., … Hamlin, P. A. (2018). The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial
Bagot, M., Porcu, P., William, B. M., Battistella, M., Vermeer, M., Whittaker, S., … Kim, Y. H. (2018). IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial. BLOOD, 132. -
The Combination of Duvelisib, a PI3K-delta,gamma Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts
Horwitz, S. M., Moskowitz, A. J., Jacobsen, E. D., Mehta-Shah, N., Khodadoust, M. S., Fisher, D. C., … Weinstock, D. M. (2018). The Combination of Duvelisib, a PI3K-delta,gamma Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts. BLOOD, 132. -
Volumetric modulated arc therapy and 3-dimensional printed bolus in the treatment of refractory primary cutaneous gamma delta lymphoma of the bilateral legs.
Obeid, J.-P., Gutkin, P. M., Lewis, J., Skinner, L., Wang, E. B., Khodadoust, M. S., … Hiniker, S. M. (2019). Volumetric modulated arc therapy and 3-dimensional printed bolus in the treatment of refractory primary cutaneous gamma delta lymphoma of the bilateral legs. Practical Radiation Oncology. -
Determining cell type abundance and expression from bulk tissues with digital cytometry.
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., … Alizadeh, A. A. (2019). Determining cell type abundance and expression from bulk tissues with digital cytometry. Nature Biotechnology. -
Low-dose Total Skin Electron Beam Therapy for Refractory Cutaneous CD30 Positive Lymphoproliferative Disorders.
Panjwani, N., Yoo, C. H., Wang, E., Khodadoust, M. S., Kim, Y. H., Hoppe, R. T., & Hiniker, S. M. (2019). Low-dose Total Skin Electron Beam Therapy for Refractory Cutaneous CD30 Positive Lymphoproliferative Disorders. The Journal of Dermatological Treatment, 1–5. -
TNFR2-targeted elimination of Tregs and tumor-residing T cells in advanced cutaneous T cell lymphoma
Faustman, D. L., Torrey, H., Khodadoust, M., Defusco, A., Baum, D., Rahbar, Z., & Kim, Y. H. (2018). TNFR2-targeted elimination of Tregs and tumor-residing T cells in advanced cutaneous T cell lymphoma. CANCER RESEARCH, 78(13). -
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Bagot, M., Porcu, P., Marie-Cardine, A., Battistella, M., William, B. M., Vermeer, M., … Kim, Y. H. (2019). IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. The Lancet. Oncology. -
Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs
Obeid, J.-P., Gutkin, P. M., Lewis, J., Skinner, L., Wang, E. B., Khodadoust, M. S., … Hiniker, S. M. (2019). Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs. PRACTICAL RADIATION ONCOLOGY, 9(4), 220–25. -
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.
Narayan, R., Olsson, N., Wagar, L. E., Medeiros, B. C., Meyer, E., Czerwinski, D., … Levy, R. (2019). Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. PloS One, 14(7), e0219547. -
Determining cell type abundance and expression from bulk tissues with digital cytometry
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., … Alizadeh, A. A. (2019). Determining cell type abundance and expression from bulk tissues with digital cytometry. NATURE BIOTECHNOLOGY, 37(7), 773-+. -
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Khodadoust, M. S., Rook, A. H., Porcu, P., Foss, F., Moskowitz, A. J., Shustov, A., … Kim, Y. H. (2019). Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1901056. -
Predicting HLA class II antigen presentation through integrated deep learning.
Chen, B., Khodadoust, M. S., Olsson, N., Wagar, L. E., Fast, E., Liu, C. L., … Alizadeh, A. A. (2019). Predicting HLA class II antigen presentation through integrated deep learning. Nature Biotechnology. -
Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma
Shree, T., Khodadoust, M. S., Czerwinski, D., Frank, M. J., Hong, W. X., Greenstein, R., … Levy, R. (2019). Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma. CANCER RESEARCH, 79(13). -
Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and oncogenes expressed on the tumor
Khodadoust, M., Kim, Y., Yang, M., Torrey, H., Tran, L., & Faustman, D. (2019). Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and oncogenes expressed on the tumor. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC. -
A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival.
Hoffmann, J. C., Atwater, S. K., Hong, E., Kumar, J., Khodadoust, M., Kim, Y., & Ohgami, R. S. (2020). A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival. The American Journal of Dermatopathology, 42(6), 389–96. -
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9). -
Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
Weng, W.-K. K., Arai, S., Rezvani, A., Johnston, L., Lowsky, R., Miklos, D., … Kim, Y. H. (2020). Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 4(18), 4474–82. -
Histopathologic Characterization of Mogamulizumab-associated Rash.
Wang, J. Y., Hirotsu, K. E., Neal, T. M., Raghavan, S. S., Kwong, B. Y., Khodadoust, M. S., … Rieger, K. E. (2020). Histopathologic Characterization of Mogamulizumab-associated Rash. The American Journal of Surgical Pathology. -
Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports.
Rojansky, R., Fernandez-Pol, S., Wang, E., Rieger, K. E., Novoa, R. A., Zehnder, J. L., … Brown, R. A. (2020). Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports. Diagnostic Pathology, 15(1), 122. -
Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2 Domain Mutations.
Fernandez-Pol, S., Petersen, B., Murphy, J.-E., Oak, J. S., Wang, E. B., Rieger, K. E., … Suarez, C. J. (2020). Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2 Domain Mutations. The American Journal of Surgical Pathology. -
Pembrolizumab in mycosis fungoides with PD-L1 structural variants.
Beygi, S., Fernandez-Pol, S., Duran, G., Wang, E. B., Stehr, H., Zehnder, J. L., … Khodadoust, M. S. (2021). Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Advances, 5(3), 771–74. -
Cellular neighborhoods predict pembrolizumab response in cutaneous T cell lymphoma
Schurch, C. M., Phillips, D. J., Gutierrez, B. R., Matusiak, M., Bhate, S. S., Barlow, G. L., … Nolan, G. P. (2020). Cellular neighborhoods predict pembrolizumab response in cutaneous T cell lymphoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sezary Syndrome.
Fong, S., Hong, E. K., Khodadoust, M. S., Li, S., Hoppe, R. T., Kim, Y. H., & Hiniker, S. M. (2021). Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sezary Syndrome. Advances in Radiation Oncology, 6(3), 100629. -
Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome.
Hirotsu, K. E., Neal, T. M., Khodadoust, M. S., Wang, J. Y., Rieger, K. E., Strelo, J., … Kwong, B. Y. (2021). Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome. JAMA Dermatology. -
Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation.
Wu, Y. F., Skinner, L., Lewis, J., Khodadoust, M. S., Kim, Y. H., Kwong, B. Y., … Hiniker, S. M. (2021). Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation. Cancer Investigation, 1–11. -
Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging
Phillips, D., Schuerch, C. M., Khodadoust, M. S., Kim, Y. H., Nolan, G. P., & Jiang, S. (2021). Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging. FRONTIERS IN IMMUNOLOGY, 12, 687673. -
Primary Cytotoxic T Cell Lymphomas Harbor Recurrent Targetable Alterations in the JAK-STAT Pathway.
Lee, K., Evans, M. G., Yang, L., Ng, S., Snowden, C., Khodadoust, M. S., … Choi, J. (2021). Primary Cytotoxic T Cell Lymphomas Harbor Recurrent Targetable Alterations in the JAK-STAT Pathway. Blood. -
Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study.
Kim, Y. H., Khodadoust, M., de Masson, A., Moins-Teisserenc, H., Ito, T., Dwyer, K., … Bagot, M. (2021). Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study. European Journal of Cancer (Oxford, England : 1990), 156 Suppl 1, S48–S49. -
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.
Phillips, D., Matusiak, M., Gutierrez, B. R., Bhate, S. S., Barlow, G. L., Jiang, S., … Nolan, G. P. (2021). Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nature Communications, 12(1), 6726. -
Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion
Fernandez-Pol, S., Neishaboori, N., Chapman, C. M., Khodadoust, M. S., Kim, Y. H., Rieger, K. E., & Suarez, C. J. (2021). Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion. JCO PRECISION ONCOLOGY, 5, 646–652. -
Mechanisms of resistance to anti-CCR4 antibody, mogamulizumab, in cutaneous T cell lymphoma
Beygi, S., Fernandez-Pol, S., Duran, G., Wang, E. B., Kim, Y., & Khodadoust, M. (2021). Mechanisms of resistance to anti-CCR4 antibody, mogamulizumab, in cutaneous T cell lymphoma. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study
Kim, Y. H., Khodadoust, M., de Masson, A., Moins-Teisserenc, H., Ito, T., Dwyer, K., … Bagot, M. (2021). Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
Primary cytotoxic T cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway
Lee, K., Evans, M. G., Yang, L., Ng, S., Snowden, C., Khodadoust, M., … Choi, J. (2021). Primary cytotoxic T cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion.
Fernandez-Pol, S., Neishaboori, N., Chapman, C. M., Khodadoust, M. S., Kim, Y. H., Rieger, K. E., & Suarez, C. J. (2021). Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion. JCO Precision Oncology, 5, 646–652. -
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.
Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., … Levy, R. (2022). CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity. Blood Cancer Discovery. -
Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma.
Beygi, S., Duran, G. E., Fernandez-Pol, S., Rook, A. H., Kim, Y. H., & Khodadoust, M. S. (2022). Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma. Blood. -
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.
Su, T., Duran, G. E., Kwang, A. C., Ramchurren, N., Fling, S. P., Kim, Y. H., & Khodadoust, M. S. (2022). Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome. Oncoimmunology, 11(1), 2115197. -
Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
Shree, T., Shankar, V., Czerwinski, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., … Levy, R. (2021). Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation
Shree, T., Haebe, S., Czerwinski, D. K., Day, G., Sathe, A., Khodadoust, M. S., … Levy, R. (2021). Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation. BLOOD. AMER SOC HEMATOLOGY. -
Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral TCell Lymphoma
Horwitz, S. M., Feldman, T. A., Ye, J. C., Khodadoust, M. S., Munoz, J., Hamlin, P. A., … Smith, S. M. (2021). Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral TCell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Integrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome.
Khodadoust, M. S., Mou, E., & Kim, Y. H. (2022). Integrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome. Blood.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma »
- Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma »
- Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma »
- Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome »
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas »
- NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) »
- TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma »
- Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) »
Practice Locations
Lymphoma Program Palo Alto, CA
Palo Alto, CA
Lymphoma Program
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Lymphoma Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Lymphoma Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(56 reviews)
Great "bedside" manner
Dr Khodadoust is the best.
Great Staff!
Dr. Khodadoust, his Physician's Assistant, Sam and Myrna, RN Assistant are the best!
Dr Khodadoust. And his staff, Dr.Eckert and Mayra Lozano are wonderful
I am blessed to have such a multi-disciplinary approach team working tirelessly on my behalf. Best place ever for medical expertise and genuine care.!! :-)
I am very grateful and thankful for having the opportunity to have met and have Dr. Youn Kim and Dr. Michael Khodadoust as care providers, who have provided me with excellent care, throughout the past year.
Definitely to recommend to other patients with Lymphoma
Pleasantly Professional! Thorough with complete information. Caring. Detail oriented.
Drs khodaghost & Kim are the best ! and so kind
I enjoy meeting with Dr. Khadadoust. He is very personable and knowledgable.
Met first with Samantha Kramer, NP. She also was very personable, knowledgable and helpful.
All doctors, nurses and medical assistants are outstanding.
Outstanding providers.
Excellent bed side manner as well as his staff
He is the best
There were 2 primary providers. Both were beyond wonderful! Both knowledgeable and both with advanced experience, including great empathy!
Dr. Khodadoust and Dr. Kim are both great!!
I've always had the best best experience!
Dr. Khodadoust was aware my teenage son had an appointment at the same time and made a special point of getting me in and out so I can could join him. Pretty amazing! (Certainly above & beyond).
Dr. Khodadoust's team is wonderful.
Very thorough when checking me. Always explaining everything to me. Very polite.
Excellent.
Would recommend Dr. Khodadoust highly.
With Dr. Khodadoust I know I am in the absolute best care. He explains all of my questions thoroughly and I trust him and his advice 100%. I am so thankful that he is my doctor. Quan Thai is also extremely helpful and responsive. Thank you both!
Drs. Kim & Khodadoust have saved my life.
Everyone is always caring and concerned.
Doctors, nurses and staff are very friendly and courteous.
The attention was very good.
Dr. Khodadoust & his team (Dr. Quan) are very good to me communicating, explaining, plans & treatments.
Dr. Khodadoust and his NP are great.
I have only one appointment to comment on - Dr. Khodadoust was very professional yet understanding, and personable. Everything I was hoping for as I begin this new phase of my life.
Dr. Khodadoust is exceptional!
Dr. Khodadoust is one of the best doctors I have ever worked with.
Dr. Khodadoust seemed more an observer than active participant during this visit. Drs. Kim & Hoppe spoke more to me, then the 3 doctors conversed among themselves. I met Dr. Khodadoust the first time I came to Stanford and I remember him as courteous & gentle.
Very good care providers.
Dr. Khodadoust has a very caring manner.
Dr. Khodadoust is the BEST!
Dr. Khodadoust has a great "bedside manner".
Dr. Michael is a very caring and efficient physician!
Very good.
Dr. Kim and here entire staff are off-the-charts fabulous in every way. Dr. Kim is as brilliant as she is warm. Their care brought tears to my eyes.
Dr. Khodadoust is very responsive, patient and has the ability to explain issues very well.
The best doctor I've ever had!
Very good.
Excellent doctors.
I have been in excellent care throughout my chemo treatments and after - I consider Dr. K had a decent one of your finest doctors dealing with. Lymphoma patients at Stanford Medical - and so very caring and nice -
The doctors were fabulous -
My Dr. "K" was exceptionally kind and concerned in my treatment of lymphoma of the blood cells (non-Hodgkin's) kept me informed - easy to talk to and well liked by me and my family "team" - He is the BEST!!
Dr. Khodadoust was an excellent provider he answered all my questions completely & professionally.
The doctor showed genuine concern, made me feel as is if he was in a hurry, I felt very relaxed with him. He listened, gave me time to ask questions, and his answers were complete and very helpful. We left the initial appointment feeling that my decision to come to Stanford will be turning point in 20+ year history if care.
Dr. Khodadoust has the best bedside manner. He takes as much time as needed to make on comfortable and explains things so I can understand. I can't thank him enough as well as the team for the care they have provided.
I feel blessed to be under Dr. Khodadoust's care! He is beyond wonderful.
Dr. Khodadoust explained my condition & treatment options clearly, thoroughly & in language I could understand.
Dr. K explained my situation as well as the study in layman's terms. I was able to understand & was treated with courtesy & respect.
Dr. Khodadoust has been an outstanding care provider - with sincere concern about my treatment and pain management.
I feel very comfortable and at ease w/Dr. Khodadoust.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or e-mail the Referral Center at ReferralCenter@stanfordhealthcare.org
- Send referrals online
- View referral status
- Access medical records